Stock Analysis
Stryker Corporation (SYK) Stock Analysis
Stryker Corporation (SYK) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Stryker Corporation (SYK) currently has an AIQ Score of 43/100, indicating a neutral setup. Quality is the strongest factor at 66/100. Momentum is the weakest current factor at 8/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
SYK at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $275.56 |
| AIQ Score | 43/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Strong Sell |
| Market Cap | $121.68B |
| P/E Ratio | 23.7 |
| Forward P/E | — |
| EPS | $3.32 |
| Revenue TTM | $6.59B |
| Dividend Yield | 0.00% |
| Beta | 0.77 |
| Volume | 3.73M |
| 52-week range | $267.00-$392.95 |
| RSI 14 | 19.27 |
| 50-Day SMA | $325.03 |
| 200-Day SMA | $336.68 |
| Analyst Price Target | $375.11 |
| Next Earnings | Oct 29, 2026 |
SYK
OverviewSYK Stock Analysis Summary
Stryker Corporation (SYK) currently has an AIQ Score of 43/100, indicating a neutral setup. Quality is the strongest factor at 66/100. Momentum is the weakest current factor at 8/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, SYK has AIQ Score of 43/100 with Quality base of 66/100 and fading Momentum at 8/100. Wait for component alignment before adding exposure.
Quality (66/100) leads while Momentum (8/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · 2.06% stock move · SYK classified in Medical - Devices.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is SYK Bullish or Bearish Right Now?
SYK currently has a neutral overall setup. Quality is the strongest factor at 66/100, while Momentum is weakest at 8/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Quality is supportive at 66/100.
- - Analyst target implies +36.13% upside from the latest quote.
- - Value is the current constraint at 42/100.
- - Momentum is weak at 8/100.
- - Price is -18.15% below its 200-day SMA.
- - Technical consensus has more sell votes than buy votes (36 vs 8).
Current Consensus
SYK's Technical Analysis Consensus is currently Strong Sell, with 8 buy, 1 neutral, and 36 sell votes. SYK's 14-day RSI is 19.27, which places the stock in an oversold momentum range. SYK's beta is 0.77, indicating lower market sensitivity than the broad market.
What Changed in SYK?
Recent score-change history is not available in the current snapshot. These are the latest market-close scores instead.
What Would Change the SYK Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
SYK Decision Framework
Public evidence layers, setup checks, and risk context for Stryker Corporation.
Stryker Corporation (SYK) Stock Analysis
Stryker Corporation has an AIQ Score of 43/100 in a Neutral regime. Quality is strongest at 66/100. Beta is 0.77, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | SYK is in a Neutral AIQ regime with score 43/100. |
| Signal Conflict | The primary conflict is that quality leads at 66/100 while momentum lags at 8/100. |
| Factor Evidence | Momentum 8/100 · Value 42/100 · Quality 66/100 · Risk 55/100 · Sentiment 58/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Quality is the strongest factor at 66/100.
Momentum is 8/100 and RSI (14) is 19.3.
SYK is in a Neutral regime at 43/100.
Risk factor is 55/100 with beta 0.77 and annual volatility 29.49%.
Current conflict: quality leads at 66/100 while momentum lags at 8/100.
SYK Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
SYK Fundamentals
SYK valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
SYK Technical Analysis
SYK technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
SYK Stock Catalysts
Track SYK earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
SYK Dividend Analysis
SYK dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
SYK Financial Data
SYK revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
SYK Risk Analysis
SYK volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
SYK Stock News
SYK stock news, market tone, recent headlines, and catalyst context.
SYK vs Medical Devices Peers
Current peer cohort: SYK · TFX · TMDX · VTRS · WAT. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| SYK Current stock | 43/100 | 42/100 | 8/100 | 55/100 | -1.1 | 29.49% | Current |
| TFX Teleflex | 47/100 | 62/100 | 29/100 | 64/100 | 0.12 | 40.39% | SYK vs TFX |
| TMDX TransMedics | 42/100 | 32/100 | 34/100 | 33/100 | -0.25 | 57.57% | SYK vs TMDX |
| VTRS Viatris | 54/100 | 73/100 | 51/100 | 64/100 | 1.53 | 32.17% | SYK vs VTRS |
| WAT Waters Corporation | 47/100 | 32/100 | 52/100 | 65/100 | 1 | 36.07% | SYK vs WAT |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Sep 11, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts7 recent quarterly periods are available for review.
Checked Sep 12, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching SYK
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for SYK
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
SYK Stock FAQ
What is SYK stock price today?
Stryker Corporation's current stock price is $275.56. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is SYK bullish or bearish right now?
SYK's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is SYK's market cap?
SYK's market cap is $121.68B based on the latest completed market-close snapshot from Sep 11, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is SYK's current P/E ratio?
SYK's current P/E ratio is 23.7 based on the latest completed market-close snapshot from Sep 11, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is SYK's RSI?
SYK's 14-day RSI is 19.27 based on the latest completed market-close snapshot from Sep 11, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is SYK above its 50-day and 200-day moving averages?
SYK is -15.22% from its 50-day SMA and -18.15% from its 200-day SMA based on the latest completed market-close snapshot from Sep 11, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is SYK's next earnings date?
SYK's next earnings date is currently listed as Oct 29, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does SYK pay a dividend?
SYK's dividend yield is 0.00% based on the latest completed market-close snapshot from Sep 11, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.